BioCryst Pharmaceuticals Inc. (NASDAQ:BDRX) is a pharmaceutical research company founded in 1986 in Birmingham as a spin-off of UAB research. It went public in 1994 and is currently headquartered in Raleigh, North Carolina, with research operations at its "Discovery Research Center and Laboratory Center of Excellence" in Birmingham.
Formerly headquartered at 2190 Parkway Lake Drive, BioCryst develops and manufactures various types of perscription drugs. Its two most well-known products include the influenza drug Peramivir, a treatment of T-cell mediated disorders called BCX-1777 and another treatment for T-cell mediated autoimmune diseases called BCX-4208.
BioCryst is developing the following drug treatments:
- Fodosine IV, for treatment of T-cell leukemia (Phase II/IIb)
- Fodosine Oral, for treatment of cutaneous T-cell lymphoma (Phase I/II)
- Fodosine Oral, for treatment of chronic lymphocytic leukemia (Phase I/II)
- Fodosine IV, for treatment of B-cell acute lymphoblastic leukemia (Phase I/II)
- BCX-4208 Oral, for treatment of autoimmune diseases/transplantation (Phase I)
- Peramivir IV/IM, for treatment of seasonal/life-threatening influenza (Phase I)
- BCX-4208 Oral, for treatment of Hepatitis C
- BioCryst Pharmaceuticals, Inc. (2005) Corporate Report 2005 (PDF) - accessed September 21, 2006
- BioCryst Pharmaceuticals Inc. corporate spotlight at NASDAQ. - Accessed September 21, 2006
- Hubbard, Russell. (September 21, 2006) "BioCryst says CEO will retire in 2007." Birmingham News
- DeButts, Jimmy (November 13, 2009) "BioCryst sees healthy future after flu drug." Birmingham Business Journal
- Piper, Ben (October 13, 2010) "BioCryst Pharmaceuticals Inc. moving HQ to North Carolina." Birmingham Business Journal
- BioCryst Pharmaceuticals Inc. website